ESMO poster | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1531 of 1645  at  9/30/2019 9:14:47 PM  by


 In response to msg 1530 by  raferjack
view thread

Re: ESMO poster

 Clinical activity across multiple hard to treat traditionally immune-unresponsive tumor types as a single agent.
Confirms abscopal effect across multiple tumor types.
Improved antigen presentation in the tumor microenvironment.
Further confirms mechanism of action and rationale for use with CPI's.

Stable disease with low toxicity is the new goal in these difficult to treat tumor types.
Safety profile remains stellar.
Adds to and supports everything that has been postulated thus far. Predicts likely very good results when a CPI is added.
No treatment options available for most of these refractory stage IV patients.
No earth shattering headlines here, but further foundation building for expansion into multiple solid tumors ( huge market) and approval.
Likelihood that pairing with many CPI's and/or other immunologic agents is possible based on safety and predictable enhancement of the microenvironment.
All good. Keep building.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 139
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by